HIV HBV co-infections : epidemiology, natural history, and treatment : a review article

Abstract EN

Hepatitis B virus (HBV) infection, one of the major health priorities, accounts approximately for 350 million chronic cases and a global total of 33 million people were living with human immunodeficiency virus (HIV) in the world.

Co-infection with HIV and the HBV presents a significant challenge to health care providers, with different prevalence rates in different parts of the world.

It is important to screen all HIV infected individuals for HBV infection and reverse.

Infection with HBV becomes more violent in patients co-infected with human immunodeficiency syndrome.

HIV / HBV co-infected individuals are at increased risk of chronic hepatitis, cirrhosis, and hepatocellular carcinoma, and of experiencing HAART toxicity.

In this review, the latest statistics on epidemiology of HIV, HBV and their co-infection has been presented along with prominent characteristics of HBV.

Transmission routes which are the common between HBV and HIV are described and the most important ones are described according to the regional and age features.

Also, there is a series of actions being performed once HBV infections occur to prevent HIV or to diagnose if the HBV-infected individuals are also infected with HIV.

As in treatment case, some of the frequent treatment methods including applying interferon and using nucleoside and nucleotide analogues have been discussed.

Finally, we would explain the new recommendations for treating patients who were co-infected with HBV and HIV, including staging HBV and HIV treatment, based on the stage of each disease.

It also outlines the optimal treatment options, whether the patient is treated for HBV first, HIV first, or HIV and HBV together.